Caballero-Borrego Miguel, Grau Juan J, Basté Neus, Castillo Paola C, Teixido Cristina, Valduvieco Izaskun, Vilaseca Isabel
Hospital Clinic of Barcelona, Otolaryngology Department, Barcelona, Spain; Universitat de Barcelona, Facultat de Medicina i Ciències de la Salut, Department of Surgery and Medical-Surgical Specialties, Barcelona, Spain; Institut d'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS), Barcelona, Spain.
Hospital Clínic, Department of Medical Oncology, Barcelona, Spain.
Braz J Otorhinolaryngol. 2025 Jul 29;91(6):101689. doi: 10.1016/j.bjorl.2025.101689.
To analyze the presence of cancer stem cells markers in consecutive patients with locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) and establish their suitability as a prognostic biomarker in samples from routine practice.
Retrospective study of 104 consecutive patients with locally advanced HNSCC treated with definitive surgery and adjuvant chemoradiotherapy. Immunohistochemical expression of CD44, HLA-I, pan-cytokeratin, and phosphorylated Epidermal Growth Factor Receptor (p-EGFR) were evaluated in surgical specimens. Overall Survival (OS) and Disease-Free Survival (DFS) rates were calculated based on clinical characteristics and the total positive score (for tumor marker expression). Hazard ratios were calculated by Cox multivariate analysis.
After a median follow-up of 50-months, higher OS rates were observed for patients without cervical node pathological involvement (p < 0.001), patients with HLA-I overexpression and a total positive score ≥ 15% (p = 0.017), and patients with low CD44 expression and a total positive score ≤ 60% (p = 0.022). Grouping by p-EGFR (p = 0.648) or pan-cytokeratin (p = 0.477) expression did not show statistical differences in OS. None of the biomarkers were associated with different DFS rates. Cox multivariate analysis revealed that positive cervical nodes (HR = 1.294; 95% CI 1.025-1.634; p = 0.030) and the expressions of HLA (HR = 0.373; 95% CI 0.168‒0.829; p = 0.015) and CD44 (HR = 2.170; 95% CI 1.031-4.569; p = 0.041) were independently associated with OS.
Nodal involvement, HLA-I overexpression, and decreased CD44 expression are independent prognostic factors of survival in patients with locally advanced HNSCC.
III.
分析局部晚期头颈部鳞状细胞癌(HNSCC)连续患者中癌症干细胞标志物的存在情况,并确定其在常规实践样本中作为预后生物标志物的适用性。
对104例接受根治性手术和辅助放化疗的局部晚期HNSCC连续患者进行回顾性研究。评估手术标本中CD44、HLA-I、全细胞角蛋白和磷酸化表皮生长因子受体(p-EGFR)的免疫组化表达。根据临床特征和总阳性评分(肿瘤标志物表达)计算总生存期(OS)和无病生存期(DFS)率。通过Cox多因素分析计算风险比。
中位随访50个月后,无颈淋巴结病理受累的患者(p < 0.001)、HLA-I过表达且总阳性评分≥15%的患者(p = 0.017)以及CD44低表达且总阳性评分≤60%的患者(p = 0.022)的OS率较高。按p-EGFR(p = 0.648)或全细胞角蛋白(p = 0.477)表达分组在OS方面未显示统计学差异。没有一种生物标志物与不同的DFS率相关。Cox多因素分析显示,阳性颈淋巴结(HR = 1.294;95%CI 1.025 - 1.634;p = 0.030)以及HLA(HR = 0.373;95%CI 0.168 - 0.